Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of May 2026. The report discloses a specific transaction under the Deferred Investment Award Programme involving a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data presented relates to a specific executive compensation transaction:
- Instrument: Notional Ordinary Shares (ISIN: GB00BN7SWP63)
- Transaction Price: £19.01 per share
- Transaction Volume: 35,507.628 shares
- Total Notional Value: Approximately £675,000 (calculated from price and volume)
Material Changes
The filing reports the appointment of Roanne Parry as Chief People Officer and a newly appointed Executive Committee member. Consequently, on May 1, 2026, she was granted a restricted award of notional Ordinary Shares. This is an initial notification of the transaction.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, financial outlook, or general management commentary regarding the company's strategic direction. The document focuses solely on the mechanics of the award:
- Vesting Schedule: The award vests in two increments: 34.22% on August 31, 2028, and 65.78% on August 31, 2029.
- Conditions: Vesting is subject to the PDMR remaining in service and not being terminated for cause.
- Payout: Dividends accrue during the vesting period, and the award is paid in cash upon vesting.
- Eligibility: Executive Directors are explicitly noted as ineligible for this specific programme.
Investor Verification Checklist
- Verify the appointment of Roanne Parry as Chief People Officer and her status as a PDMR.
- Confirm the terms of the Deferred Investment Award Programme, specifically the cash-settlement nature and vesting conditions.
- Note that this filing does not contain quarterly or annual financial performance data; investors should refer to Form 20-F for comprehensive financial results.
- Check for any subsequent filings regarding the vesting of this award in 2028 and 2029.